Ocular moisture enhancement

Ocular moisture enhancement" refers to therapeutic approaches and agents that increase or preserve water content and lubrication on the ocular surface to alleviate dry eye disease and related symptoms. This is not a molecular target itself, but a therapeutic goal achieved using various agents such as artificial tears, hyaluronic acid, osmoprotectants (like trehalose and L-carnitine), omega-3 fatty acids, and anti-inflammatory medications. Molecular mechanisms of dryness and moisture loss involve tear film instability, hyperosmolarity, inflammation, oxidation, and reduced secretion from glands such as the lacrimal and meibomian glands. Drugs and interventions are categorized by their ability to physically supplement tears, reduce tear evaporation, protect epithelial cells, or modulate inflammation, but do not act through a single molecule or receptor as a drug target[1][2][3][4][5]. In summary, "ocular moisture enhancement" is not a canonical molecule or receptor and thus should not be treated as a molecular therapeutic target for structured biomedical data.

Other names

Ocular surface hydrationTear film enhancementOcular lubricationDry eye treatment

Physical moisture retention or lubrication; Osmoprotection against hyperosmolar stress; Anti-inflammatory actions; Stimulation of tear secretion; Protection of ocular surface epithelial cells